The Immunology Podcast cover image

Ep. 29: “Immuno-Oncology Therapeutics” Featuring Dr. Michael Alonso

The Immunology Podcast

00:00

Is There a Difference Between Myeloid Cells and T Cells?

BDC 1001 and some of these other her two target agonists, utilizing other pathways to get NF Kappa B and do signaling. And then we get a very diverse T cell population that can mediate, you know, hopefully long-term responses. It certainly did in our preclinical models. I'm always, I always like when the T cells come to rescue that.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app